“Intestinal barrier healing is superior to endoscopic and histologic remission for predicting major adverse outcomes in IBD: the prospective ERIca trial”

Quazim Alayo, MD, MMSc

&

“Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial”

Siri Ancha, MD

Please Contact Beth Buschard-Steiger (bbuscha@wustl.edu) for Zoom Details